Related Experiment Videos
Antithrombotic therapy in patients with heart valve prostheses
Hadewich Hermans1, Thomas Vanassche, Paul Herijgers
1Department of Cardiovascular Medicine, University of Leuven, Belgium.
Cardiology in Review
|June 15, 2012
Summary
Patients with heart valve prostheses need antithrombotic therapy to prevent clots. Current evidence is limited, necessitating a reevaluation of optimal anticoagulant and antiplatelet strategies for these patients.
Area of Science:
- Cardiology
- Hematology
Background:
- Heart valve prostheses increase thrombosis risk, necessitating antithrombotic strategies.
- Existing clinical trial data may not reflect current prostheses, patient demographics, or therapies.
- Limited evidence leads to varied recommendations on anticoagulation intensity and antiplatelet use.
Purpose of the Study:
- To highlight the need for updated guidelines on antithrombotic treatment for heart valve prostheses.
- To address the scarcity of contemporary randomized trials in this field.
- To underscore the importance of redefining antithrombotic strategies due to new agents and evolving risks.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of current recommendations from scientific societies.
- Assessment of the impact of new antithrombotic agents and changing prostheses characteristics.
Main Results:
- Scarcity of contemporary randomized trials guiding optimal anticoagulant treatment.
- Divergent recommendations on oral anticoagulation intensity and antiplatelet therapy indications.
- Unclear thrombotic risk associated with current heart valve prostheses.
Conclusions:
- There is a critical need to redefine antithrombotic treatment for patients with heart valve prostheses.
- Updated evidence is required to guide clinical decisions on anticoagulation and antiplatelet therapy.
- The evolving landscape of prostheses and therapies necessitates a reevaluation of established protocols.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.